Tuesday, October 19

A second study agrees on the cause of thrombi linked to the AstraZeneca vaccine: platelets


Madrid

Updated:

Keep

A protein called platelet factor 4 or FP4 is the one that has been able to originate the thrombi developed by 16 people in Germany, Austria and Norway, after being vaccinated with AstraZeneca serum, according to two studies published in the American journal ‘The New England Journal of Medicine’.

The first of them analyzes the case of 11 vaccinated patients in Germany and Austria who had developed thrombosis after being inoculated with the British serum; nine were women, with a mean age of 36 years (from the age range of 22 to 49 years). Between 5 and 16 days after vaccination, patients experienced one or more thrombotic events, with the exception of one patient, who had a fatal intracranial hemorrhage.

Of the patients with one or more thrombotic episodes, 9 had cerebral venous thrombosis, 3 had splanchnic venous thrombosis (in the liver), 3 had pulmonary embolism, and 4 had other kinds of thrombosis; of all of them, 6 died and 5 patients had disseminated intravascular coagulation.

Although the thromboses affected different organs, all patients had antibodies against FP4 protein and a deficiency of platelets in the blood.

The study, funded by the German Research Foundation, concludes that vaccination with AstraZeneca serum “May lead to the rare development of immune thrombosis mediated by platelet activating antibodies against FP4.”

Second study

The second study looks at the situation of the five patients from Norway: four women and one man between the ages of 32 and 54 who were healthcare workers and who developed symptoms between the seventh and tenth day after receiving the first dose of the vaccine.

All patients developed thrombi in unusual places; one had severe thrombocytopenia, and four had a major brain hemorrhage (three died).

As in the previous study, they all had high levels of antibodies against platelet protein FP4, a reaction induced by the vaccine. The study – from the University of Oslo – points out that since the five cases were registered among more than 130,000 vaccinated people, it is a rare reaction.

See them
comments


www.abc.es

Leave a Reply

Your email address will not be published. Required fields are marked *

Share